Prodigiosin Sensitizes Sensitive and Resistant Urothelial Carcinoma Cells to Cisplatin Treatment

Cisplatin-based treatment is the standard of care therapy for urothelial carcinomas. However, complex cisplatin resistance mechanisms limit the success of this approach. Both apoptosis and autophagy have been shown to contribute to this resistance. Prodigiosin, a secondary metabolite from various ba...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Molecules
Main Authors: Berning, Lena, Schlütermann, David, Friedrich, Annabelle, Berleth, Niklas, Sun, Yadong, Wu, Wenxian, Mendiburo, María José, Deitersen, Jana, Brass, Hannah U. C., Skowron, Margaretha A., Hoffmann, Michèle J., Niegisch, Günter, Pietruszka, Jörg, Stork, Björn
Formato: Artigo
Idioma:Inglês
Publicado em: MDPI 2021
Assuntos:
Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC7957586/
https://ncbi.nlm.nih.gov/pubmed/33673611
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3390/molecules26051294
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados